NASDAQ
23.77USD
+3.55 (+17.56%)
We have scored 10 news catalysts on SI-BONE, Inc. (SIBN) over the past 12 months. The biggest single-day move next to one of them came May 12, 2026, when SIBN closed +19.7%: “SiBone Q1 Earnings Call Highlights”. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in short squeeze potential and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.1B
P/E
—
EPS
—
Beta
0.64
52W range
11.48-23.93
Day range
19.07–23.90
Open
19.33
Prev close
20.22
Volume
3.3M
Avg volume
619.7K
Dividend
0.00
IPO
2018-10-17
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about SI-BONE, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SIBN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
